Prothena Corp Public (PRTA) Cash & Current Investments (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Cash & Current Investments of $329.5 million in Q1 2026, up 7.13% quarter-over-quarter from $307.5 million in Q4 2025, and down 21.17% on a YoY basis from $417.9 million in Q1 2025.
Prothena Corp Public (PRTA) Cash & Current Investments (2012 - 2026) Analysis & Trends
Prothena Corp Public's Cash & Current Investments history runs 15 years deep, the most recent figure standing at $329.5 million for Q1 2026.
- In Q1 2026, Cash & Current Investments fell 21.17% year-over-year to $329.5 million; the TTM figure through Mar 2026 stood at $329.5 million (down 21.17% YoY), while the FY2025 annual figure was $307.5 million, down 34.76% from the prior year.
- Cash & Current Investments was $329.5 million for Q1 2026 at Prothena Corp Public, up from $307.5 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $710.4 million in Q4 2022 to a low of $307.5 million in Q4 2025.
- Historically, Cash & Current Investments has averaged $515.1 million across 5 years, with a median of $519.3 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Cash & Current Investments soared 57.69% in 2022, then tumbled 36.29% in 2025.
- A 5-year view of Cash & Current Investments shows it stood at $710.4 million in 2022, then decreased by 12.7% to $620.2 million in 2023, then decreased by 23.99% to $471.4 million in 2024, then tumbled by 34.76% to $307.5 million in 2025, then increased by 7.13% to $329.5 million in 2026.
- The last three Cash & Current Investments figures came in at $329.5 million (Q1 2026), $307.5 million (Q4 2025), and $330.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 329.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329.46 Mn |
| Dec 31, 2025 | 307.53 Mn |
| Sep 30, 2025 | 330.80 Mn |
| Jun 30, 2025 | 371.40 Mn |
| Mar 31, 2025 | 417.94 Mn |
| Dec 31, 2024 | 471.39 Mn |
| Sep 30, 2024 | 519.26 Mn |
| Jun 30, 2024 | 564.12 Mn |
| Mar 31, 2024 | 547.86 Mn |
| Dec 31, 2023 | 620.18 Mn |
| Sep 30, 2023 | 672.25 Mn |
| Jun 30, 2023 | 660.46 Mn |
| Mar 31, 2023 | 686.18 Mn |
| Dec 31, 2022 | 710.41 Mn |
| Sep 30, 2022 | 495.63 Mn |
| Jun 30, 2022 | 508.80 Mn |
| Mar 31, 2022 | 542.99 Mn |
| Dec 31, 2021 | 579.09 Mn |
| Sep 30, 2021 | 600.10 Mn |
| Jun 30, 2021 | 401.18 Mn |